Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
IBER.WS
IBER.WS was delisted on the 15th of February, 2023.
1 hedge funds and large institutions have $108K invested in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 32 closing their positions.
94% less capital invested
Capital invested by funds: $1.78M → $108K (-$1.68M)
97% less funds holding
Funds holding: 33 → 1 (-32)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 32
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$1.51M |
| 2 |
DMKJ
David M. Knott Jr
|
-$207K |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
-$16K |
| 4 |
CAC
Cowen and Company
New York
|
-$4.47K |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$4.06K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Walleye Trading
New York
| – | -$712 | -40,000 | Closed |
|
|
AA
27
AQR Arbitrage
Greenwich,
Connecticut
| – | -$668 | -37,500 | Closed |
|
|
WA
28
Whitebox Advisors
Minneapolis,
Minnesota
| – | -$614 | -34,500 | Closed |
|
|
AC
29
Ayrton Capital
Westport,
Connecticut
| – | -$505 | -28,393 | Closed |
|
|
TCM
30
Tegean Capital Management
New York
| – | -$407 | -22,855 | Closed |
|
|
DMKJ
31
David M. Knott Jr
| – | -$207K | -18,000 | Closed |
|
32
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$25 | -14,683 | Closed |
|
IBER.WS Hedge Fund Activity: Q1 2023 in Review
1 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) for Q1 2023, worth a combined $108K — down 94% from $1.78M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of IBER.WS and 0 opened new positions — a net loss of 32 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $1.51M sold.
- 1 institutional investor held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) as of Q1 2023, down from 33 in Q4 2022.
- Funds reported $108K of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share stock for Q1 2023, down 94% quarter-over-quarter.
- 0 funds opened new Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share positions in Q1 2023 and 32 closed out, a net change of -32 holders.
- The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share seller in Q1 2023 was Radcliffe Capital Management, an estimated $1.51M sold.
Based on aggregated 13F filings for Q1 2023.